Annual Blood Cancer Cases Treatable by Bone Marrow Transplant

1.8 Million New Cases Each Year

According to 2020 estimates from the International Agency for Research on Cancer, 1.8 million new cases of blood cancers are diagnosed each year.

Breakthrough GvHD Therapy for Safer Transplants

Every three minutes, someone is diagnosed with life-threatening blood cancer, leading to around 50,000 bone marrow transplants (BMT) annually. However, 40% of BMT recipients face the deadly challenge of Graft-versus-Host Disease (GvHD), a life-threatening inflammatory disease where donor T-cells attack the patient’s healthy cells. 

HasenTech's HT-01 treatment is designed to make potentially curative bone marrow transplants safer and more effective.

 GvHD 
​Treatment Potential

HasenTech is poised to tap into a significant market with its game-changing approach to the treatment of GvHD. 
Reducing the incidence and severity of GvHD could increase bone marrow transplant procedures from 50,000 per year to an estimated 200,000 per year.

Acute GvHD Cases/Year

GvHD Cases/Year

Bone Marrow Transplants/Year

Bone Marrow Transplant
​Treatment Potential Market/Year

​Worldwide bone marrow transplant market

Hasentech
Biotech Innovation ✦ Dampening Inflammation

Led by a pioneering leadership team, HasenTech is a biotechnology firm harnessing the potential of a natural exopolysaccharide (EPS), sugars found on the surface of the harmless soil bacterium Bacillus subtilis, as a new treatment for life changing and often fatal autoimmune and inflammatory diseases.

EPS-based treatment of recipients has been shown to dampen inflammation and suppress immune responses in mice.  Further exploration holds the promise of unlocking solution for the better treatment of a wide variety of human diseases, including Graft-versus-Host Disease (GvHD), irritable bowel disease (IBD), and Crohn’s disease and others.

Leadership team